Literature DB >> 8396815

An HSV-1 mutant lacking the LAT TATA element reactivates normally in explant cocultivation.

S L Deshmane1, M Nicosia, T Valyi-Nagy, L T Feldman, A Dillner, N W Fraser.   

Abstract

In order to examine if mutations within the LAT promoter region of HSV-1 are sufficient to change the reactivation phenotype, a mutant (KOS/29) containing a deletion of the LAT TATA element was used to establish latent infections in mouse ganglia by corneal inoculation. During the acute phase of infection, KOS/29 replicated as efficiently as its wild-type parent. As previously noted, latent KOS/29 infections were totally devoid of LAT gene transcripts (Dobson A. T., Sederati F., Devi-Rao G., Flanagan J., Farrell M. J., Stevens J. G., Wagner E. K., and Feldman L. T., J. Virol. 63, 3844-3851 (1989))). However, unlike other null mutants, KOS/29 reactivated from explanted ganglia with a kinetics similar to that of the LAT competent parent. These data show that the deletion created in KOS/29, removing the LAT TATA promoter element and small upstream and downstream flanking sequences, is not enough to alter the reactivation phenotype and that efficient reactivation can occur in the absence of any detectable LAT expression during latency.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8396815     DOI: 10.1006/viro.1993.1548

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  15 in total

1.  Mutations in the 5' end of the herpes simplex virus type 2 latency-associated transcript (LAT) promoter affect LAT expression in vivo but not the rate of spontaneous reactivation of genital herpes.

Authors:  K Wang; L Pesnicak; S E Straus
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

2.  Decreased reactivation of a herpes simplex virus type 1 (HSV-1) latency-associated transcript (LAT) mutant using the in vivo mouse UV-B model of induced reactivation.

Authors:  Lbachir BenMohamed; Nelson Osorio; Ruchi Srivastava; Arif A Khan; Jennifer L Simpson; Steven L Wechsler
Journal:  J Neurovirol       Date:  2015-05-22       Impact factor: 2.643

Review 3.  Experimental investigation of herpes simplex virus latency.

Authors:  E K Wagner; D C Bloom
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

4.  The herpes simplex virus type 1 latency-associated transcript gene regulates the establishment of latency.

Authors:  R L Thompson; N M Sawtell
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

5.  Analysis of a herpes simplex virus type 1 LAT mutant with a deletion between the putative promoter and the 5' end of the 2.0-kilobase transcript.

Authors:  J Maggioncalda; A Mehta; N W Fraser; T M Block
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

6.  cis-acting elements involved in transcriptional regulation of the herpes simplex virus type 1 latency-associated promoter 1 (LAP1) in vitro and in vivo.

Authors:  K Soares; D Y Hwang; R Ramakrishnan; M C Schmidt; D J Fink; J C Glorioso
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

7.  Two open reading frames (ORF1 and ORF2) within the 2.0-kilobase latency-associated transcript of herpes simplex virus type 1 are not essential for reactivation from latency.

Authors:  M U Fareed; J G Spivack
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

8.  Herpes simplex virus type 1 DNA replication and gene expression during explant-induced reactivation of latently infected murine sensory ganglia.

Authors:  G B Devi-Rao; D C Bloom; J G Stevens; E K Wagner
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

9.  Towards an understanding of the herpes simplex virus type 1 latency-reactivation cycle.

Authors:  Guey-Chuen Perng; Clinton Jones
Journal:  Interdiscip Perspect Infect Dis       Date:  2010-02-15

10.  Herpes simplex virus type 1 latency-associated transcript (LAT) promoter deletion mutants can express a 2-kilobase transcript mapping to the LAT region.

Authors:  M Nicosia; S L Deshmane; J M Zabolotny; T Valyi-Nagy; N W Fraser
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.